Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
KEYWORDS: people, treatment, anticoagulation, dvt, committee, anticoagulation treatment, evidence, vte, recommendations, risk, cancer, agreed, clinical, use, d-dimer

◇ short-term anticoagulation when used for primary VTE prevention in people with COVID-19 (see the recommendations on VTE prophylaxis in the NICE guideline on managing COVID-19) [2023] － think about alternative diagnoses [2012, amended 2020] － tell the person that it is not likely they have PE. Discuss with them the signs and symptoms of PE and when and where to seek further medical help. [2012, amended 2020] For a short explanation of why the committee made the 2023 recommendations and how they might affect practice, see the rationale and impact section on diagnosis and initial management in people with COVID-19. Full details of the evidence and the committee's discussion are in evidence review I: diagnosing VTE in people with COVID-19. Signs or symptoms of both DVT and PE 1.1.22 For people who present with signs or symptoms of both DVT and PE, carry out initial diagnostic investigations for either DVT or PE, basing the choice of diagnostic investigations on clinical judgement. [2012] 1.2 Outpatient treatment for low-risk PE 1.2.1 Consider outpatient treatment for suspected or confirmed low-risk PE, using a validated risk stratification tool to determine the suitability of outpatient treatment. [2020] 1.2.2 When offering outpatient treatment to people
